Replies to post #147093 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

There are very few people that are eligible for and/or elect recurrent surgery -- about 25%. So the key is preventing recurrence, and upon recurrence, having something stronger like DCVax + CI + PLX-3397. Eventually the latter therapy might make its way to frontline nGBM if developed safely. However, I agree with you that new lysate charged vaccine should be made (and possibly combined with the old vaccine if some still exists at the time of recurrence). Direct is not necessarily making L obsolete, and one only need look at the scheduled L + CI colorectal trial in Germany to see that. imho.